« Back to Recent News

Improving outcome in COPD: Scott Warner MD, Cullman
Apr 5, 2012

This program will evaluate the rationale for nebulizer use in the maintenance treatment of patients with COPD on the basis of pathophysiology, device-related attributes, and patient-specific needs and preferences, among other factors. In addition, this program will use an evidence-based approach to establish the role of Perforomist (formoterol fumarate) Inhalation Solution as a long-acting, twice-daily nebulized therapy that addresses a need in the maintenance treatment of patients with COPD based on its documented clinical efficacy and safety. Lastly, to best optimize the clinical utility of maintenance nebulized long-acting beta-agonist therapy in practice, this program will define the characteristics and profiles of ideal candidates for treatment with Perforomiste Inhalation Solution.



1. RSVP thru the e-mail you received - Easiest method.
2. Please visit and complete the registration form.
3. Call 866.443.6228.
4. Send an e-mail to Please be sure to include your full name and contact number.

Shashi Kumar MD